100 related articles for article (PubMed ID: 23474009)
41. [Recent advances in molecular-targeted drugs in head and neck cancer].
Tahara M
Gan To Kagaku Ryoho; 2008 May; 35(5):745-52. PubMed ID: 18487911
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
43. Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma
Tham T; White TG; Chakraborty S; Lall RR; Ortiz R; Langer DJ; Shatzkes D; Filippi CG; Kraus D; Boockvar JA; Costantino PD
J Exp Ther Oncol; 2016 Nov; 11(4):293-301. PubMed ID: 27849340
[TBL] [Abstract][Full Text] [Related]
44. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
45. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
46. Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients.
Boyd K; Shea SM; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):372-5. PubMed ID: 23800851
[TBL] [Abstract][Full Text] [Related]
47. PD-1 inhibition enters the frontline.
Killock D
Nat Rev Clin Oncol; 2020 Feb; 17(2):69. PubMed ID: 31729474
[No Abstract] [Full Text] [Related]
48. Further clinical interpretation and implications of KEYNOTE-048 findings.
McCaw ZR; Ludmir EB; Kim DH; Wei LJ
Lancet; 2020 Aug; 396(10248):378-379. PubMed ID: 32771102
[No Abstract] [Full Text] [Related]
49. Further clinical interpretation and implications of KEYNOTE-048 findings.
Szturz P; Vermorken JB
Lancet; 2020 Aug; 396(10248):379. PubMed ID: 32771103
[No Abstract] [Full Text] [Related]
50. Further clinical interpretation and implications of KEYNOTE-048 findings.
Revannasiddaiah S; Devadas SK; Maka VV; Kilara N
Lancet; 2020 Aug; 396(10248):378. PubMed ID: 32771101
[No Abstract] [Full Text] [Related]
51. Keynote 48: Is it really for everyone?
Schoenfeld JD; Fell G; Haddad RI; Trippa L
Oral Oncol; 2020 Jun; 105():104762. PubMed ID: 32381470
[No Abstract] [Full Text] [Related]
52. A Case of Rapidly Proliferative Glomerulonephritis Secondary to Syphilis That Responded to Treatment With Penicillin.
Siddiqui RS; Sumbly V; Abrudescu A
Cureus; 2021 Feb; 13(2):e13468. PubMed ID: 33777557
[TBL] [Abstract][Full Text] [Related]
53. Management of infusion reactions associated with cetuximab treatment: A case report.
Ohshita N; Ichimaru Y; Gamoh S; Tsuji K; Kishimoto N; Tsutsumi YM; Momota Y
Mol Clin Oncol; 2017 Jun; 6(6):853-855. PubMed ID: 28588776
[TBL] [Abstract][Full Text] [Related]
54. Reply to "Keynote 48: Is it really for everyone?".
Burtness B; Ge J
Oral Oncol; 2021 Jan; 112():104983. PubMed ID: 33032941
[No Abstract] [Full Text] [Related]
55. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Bins S; Mathijssen RHJ
Lancet; 2019 Oct; 394(10206):1322-1323. PubMed ID: 31609222
[No Abstract] [Full Text] [Related]
56. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Wei W; Ji M; Wu CP; Yang X
Lancet; 2019 Oct; 394(10206):1321-1322. PubMed ID: 31609221
[No Abstract] [Full Text] [Related]
57. p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
Cohen EEW; Soulières D; Swaby RF; Harrington KJ
Lancet; 2019 Oct; 394(10206):1323. PubMed ID: 31609223
[No Abstract] [Full Text] [Related]
58. Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma.
Amirabadi A; Alami A; Ahanchian H; Ariaee N; Moazzen N
Clin Case Rep; 2021 May; 9(5):e04021. PubMed ID: 34084482
[TBL] [Abstract][Full Text] [Related]
59. Recurrent Severe Acute Kidney Injury From Immunotactoid Glomerulonephritis and Response to Rituximab.
Adilovic E; Gupta S; Hernandez F; Mattana J; Dommu A
Am J Ther; 2021 Jan-Feb 01; 28(1):e162-e164. PubMed ID: 33369920
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
